Delivery Order SPE2DB22D2206-SPE2DB25FFU84

Award Date 2/25/25
Potential Completion Date 3/18/25
Potential Value $2.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $1,292.36, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ZOLADEX 3.6 MG IMPLANT SYRNS, a specialty medication. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for...
This federal contract award, valued at $1,873.74, was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of the pharmaceutical product ZOLADEX 3.6 MG IMPLANT SYRNS, with a completion date of May 10, 2024. Amerisourcebergen, a large pharmaceutical distribution company, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,631.84, is for the delivery of ZOLADEX 10.8 MG IMPLANT SYRNS, a specialized pharmaceutical product. The contract is a Firm Fixed Price Delivery Order with a completion date of March 12, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract worth $3,509.16 to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the federal government. The contract is for the delivery of ZOLADEX 10.8 MG IMPLANT SYRNS, with a completion date of June 13, 2024. This award is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,938.54, is a Firm Fixed Price Delivery Order for the supply of ZOLADEX 3.6 MG IMPLANT SYRNS, a pharmaceutical product. The contract has an ultimate completion date of January 17, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,336.98 firm fixed-price delivery order is for the supply of ZOLADEX 10.8 MG IMPLANT SYRNS medical products. The contract has an ultimate completion date of January 21, 2025. Amerisourcebergen Drug Corp holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,263.74 firm fixed-price delivery order is for the supply of ZOLADEX 10.8 MG IMPLANT SYRNS, a medical product related to healthcare. The contract has an ultimate completion date of November 6, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,677.52 firm-fixed-price delivery order is for the supply of 4559495371 ZOLADEX 10.8 MG IMPLANT SYRNS, with a completion date of January 24, 2023. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, which enables the efficient...
This federal contract award, valued at $3,122.90, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of ZOLADEX 3.6 MG IMPLANT SYRNS, a pharmaceutical product, with a period of performance through May 10, 2024. Amerisourcebergen, a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 31,...
This federal contract award, awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, is for the delivery of ZOLADEX 10.8 MG IMPLANT SYRNS medical supplies. The contract has a ceiling value of $11,895.70 and is a Firm Fixed Price Delivery Order contract with a completion date of January 31, 2024. The contract is not associated with any set-aside designation. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that plays a...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB25FFU84
    Delivery Order

This federal contract award, valued at $2,647.76, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ZOLADEX 3.6 MG IMPLANT SYRNS, a medical product, with a performance period ending on March 18, 2025.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs.

The contract award was not designated with any set-aside requirements, indicating open competition.

Generated 5/27/25, 9:53 AM